| CPT1a expression | P-value | |
---|---|---|---|
LOW expression (N = 80) | High expression (N = 245) | ||
Number (%) | 80 (25%) | 245 (75%) | Â |
Male, n (%) | 53 (67.1) | 137 (56.6) | 0.13 |
Age, median (IQR),years | 49.00 (36.00, 61.00) | 56.00 (39.75, 65.00) | 0.054 |
BM blast, median (IQR),% | 60.00 (29.00, 81.00) | 68.00 (43.00, 81.00) | 0.179 |
WBC, median (IQR), ×109/L | 14.70 (3.65, 64.68) | 10.50 (2.38, 45.98) | 0.336 |
HB, median (IQR), g/L | 89.90 (67.75, 105.75) | 84.00 (67.75, 102.25) | 0.360 |
PLT, median (IQR),×109/L | 45.00 (22.75, 78.00) | 49.00 (26.00, 94.75) | 0.199 |
FAB classification, n (%) | Â | Â | 0.996 |
 M0 | 8 (10.0) | 22 (9.0) |  |
 M1 | 7 (8.8) | 19 (7.8) |  |
 M2 | 39 (48.8) | 122 (49.8) |  |
 M3 | 1 (1.2) | 3 (1.2) |  |
 M4 | 3 (3.8) | 10 (4.1) |  |
 M5 | 20 (25.0) | 63 (25.7) |  |
 M6 | 2 (2.5) | 4 (1.6) |  |
Genes mutations, n (%) | Â | Â | Â |
 FLT3ITD | 11 (14.1) | 49 (20.9) | 0.190 |
CEBPADM1 | 10 (13.9) | 30 (13.8) | 1 |
 NPM1 | 19 (25.0) | 63 (28.0) | 0.657 |
 DNMT3A | 5 (7.1) | 33 (15.8) | 0.073 |
 IDH1 | 19 (26.0) | 42 (20.3) | 0.325 |
 IDH2 | 7 (10.8) | 33 (16.3) | 0.323 |
ELN favorable group, n (%) | Â | Â | Â |
 Treatment, n (%)2 |  |  |  |
 CPT1A, median (IQR) | 0.58 (0.30, 0.78) | 2.79 (1.69, 4.66) |  < 0.001 |